Onesource Specialty Pharma Ltd.
NSE: ONESOURCE · Pharmaceuticals
Snapshot
Unlock Onesource Specialty Pharma Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
OneSource Specialty Pharma Limited is a biopharmaceutical company specialising in end-to-end contract development and manufacturing organisation (CDMO) services for biological drug products. The company provides comprehensive solutions across preclinical and clinical development, alongside the commercial supply of sterile injectables, drug-delivery devices, and advanced biologics.
Business Model
The company operates as a CDMO, generating revenue by providing research, development, and manufacturing services to pharmaceutical partners for complex biologics and drug-device combinations. Its service portfolio spans microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products.
- Incorporation Year:2007
Growth Outlook
Growth is driven by the expansion of its CDMO capabilities in complex injectable formats and the commercialisation of its diverse biologics pipeline. The company leverages its specialised infrastructure to support global pharmaceutical clients through various stages of drug development.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from international health authorities, where any failure to meet quality standards could disrupt manufacturing operations.
- Client Concentration. As a CDMO, the company's revenue is heavily dependent on the success and continued outsourcing requirements of its pharmaceutical partners.
- Technological Obsolescence. The rapid evolution of biopharmaceutical manufacturing technologies requires continuous capital investment to remain competitive in the global market.
- Geopolitical and Trade Risks. Operating across multiple international jurisdictions exposes the company to fluctuations in trade policies and cross-border regulatory requirements.
Start your research today
Unlock AI insights, financials, peers and live data on Onesource Specialty Pharma Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,543 Cr
TTM · consolidated
NET PROFIT
₹-49 Cr
TTM · consolidated
EPS
₹-4.24
TTM · consolidated
RETURN ON EQUITY
-0.8%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
0.9%
TTM · consolidated
P/E
-367.5×
Q1 FY27 · consolidated
EV/EBITDA
54.2x
Q1 FY27 · consolidated
EBITDA MARGIN
22.8%
TTM · consolidated
NET PROFIT MARGIN
5.6%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.2x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Onesource Specialty Pharma Ltd.ONESOURCE | ₹17,868 Cr | -367.5× | 54.19 | 27.2% | 22.8% | -0.8% | 0.9% | -16.0% |
Shilpa Medicare LimitedSHILPAMED | ₹18,083 Cr | 60.5× | 38.48 | 27.9% | 28.9% | 12.0% | 14.2% | +162.0% |
Caplin Point Laboratories Ltd.CAPLIPOINT | ₹17,759 Cr | 26.7× | 19.15 | 15.0% | 40.3% | 21.1% | 25.7% | +14.9% |
Cohance Lifesciences Ltd.COHANCE | ₹17,104 Cr | 160.8× | 49.45 | 41.2% | 16.3% | 2.1% | 3.5% | -40.7% |
Pfizer Ltd.PFIZER | ₹16,646 Cr | 22.6× | 14.94 | 10.7% | 43.1% | 17.5% | 23.2% | -30.1% |
Eris Lifesciences Ltd.ERIS | ₹16,078 Cr | 22.5× | 15.59 | 11.1% | 35.1% | 19.9% | 15.8% | -27.1% |
As of Q1 FY27
Financials
Onesource Specialty Pharma Ltd.
NSE: ONESOURCE · Pharmaceuticals
Snapshot
Unlock Onesource Specialty Pharma Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
OneSource Specialty Pharma Limited is a biopharmaceutical company specialising in end-to-end contract development and manufacturing organisation (CDMO) services for biological drug products. The company provides comprehensive solutions across preclinical and clinical development, alongside the commercial supply of sterile injectables, drug-delivery devices, and advanced biologics.
Business Model
The company operates as a CDMO, generating revenue by providing research, development, and manufacturing services to pharmaceutical partners for complex biologics and drug-device combinations. Its service portfolio spans microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products.
- Incorporation Year:2007
Growth Outlook
Growth is driven by the expansion of its CDMO capabilities in complex injectable formats and the commercialisation of its diverse biologics pipeline. The company leverages its specialised infrastructure to support global pharmaceutical clients through various stages of drug development.
Key Risks
- Regulatory Compliance. The company faces stringent regulatory oversight from international health authorities, where any failure to meet quality standards could disrupt manufacturing operations.
- Client Concentration. As a CDMO, the company's revenue is heavily dependent on the success and continued outsourcing requirements of its pharmaceutical partners.
- Technological Obsolescence. The rapid evolution of biopharmaceutical manufacturing technologies requires continuous capital investment to remain competitive in the global market.
- Geopolitical and Trade Risks. Operating across multiple international jurisdictions exposes the company to fluctuations in trade policies and cross-border regulatory requirements.
Start your research today
Unlock AI insights, financials, peers and live data on Onesource Specialty Pharma Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹1,543 Cr
TTM · consolidated
NET PROFIT
₹-49 Cr
TTM · consolidated
EPS
₹-4.24
TTM · consolidated
RETURN ON EQUITY
-0.8%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
0.9%
TTM · consolidated
P/E
-367.5x
Q1 FY27 · consolidated
EV/EBITDA
54.2x
Q1 FY27 · consolidated
EBITDA MARGIN
22.8%
TTM · consolidated
NET PROFIT MARGIN
5.6%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.2x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27